HRTX Quote, Financials, Valuation and Earnings

Esperion Therapeutics has a net margin of 6.77% compared to Heron Therapeutics's net margin of -62.24%. Heron Therapeutics's return on equity of -- beat Esperion Therapeutics's return on equity of --.

Heron Therapeutics has a consensus price target of $6.25, signalling upside risk potential of 212.5%. On the other hand Esperion Therapeutics has an analysts' consensus of $5.79 which suggests that it could grow by 366.59%. Given that Esperion Therapeutics has higher upside potential than Heron Therapeutics, analysts believe Esperion Therapeutics is more attractive than Heron Therapeutics.

Heron Therapeutics has a beta of 1.182, which suggesting that the stock is 18.163% more volatile than S&P 500. In comparison Esperion Therapeutics has a beta of 0.703, suggesting its less volatile than the S&P 500 by 29.654%.

Heron Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Esperion Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Heron Therapeutics pays -- of its earnings as a dividend. Esperion Therapeutics pays out -- of its earnings as a dividend.

Heron Therapeutics quarterly revenues are $38.9M, which are smaller than Esperion Therapeutics quarterly revenues of $65M. Heron Therapeutics's net income of $2.6M is higher than Esperion Therapeutics's net income of -$40.5M. Notably, Heron Therapeutics's price-to-earnings ratio is -- while Esperion Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Heron Therapeutics is 2.06x versus 0.93x for Esperion Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 6.77% compared to Heron Therapeutics's net margin of -49.65%. Heron Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Heron Therapeutics has a consensus price target of $6.25, signalling upside risk potential of 212.5%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that Heron Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Heron Therapeutics is more attractive than NovaBay Pharmaceuticals.

Heron Therapeutics has a beta of 1.182, which suggesting that the stock is 18.163% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Heron Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Heron Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Heron Therapeutics quarterly revenues are $38.9M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Heron Therapeutics's net income of $2.6M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Heron Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Heron Therapeutics is 2.06x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics has a net margin of 6.77% compared to Heron Therapeutics's net margin of --. Heron Therapeutics's return on equity of -- beat Plus Therapeutics's return on equity of --.

Heron Therapeutics has a consensus price target of $6.25, signalling upside risk potential of 212.5%. On the other hand Plus Therapeutics has an analysts' consensus of $9.17 which suggests that it could grow by 2293.39%. Given that Plus Therapeutics has higher upside potential than Heron Therapeutics, analysts believe Plus Therapeutics is more attractive than Heron Therapeutics.

Heron Therapeutics has a beta of 1.182, which suggesting that the stock is 18.163% more volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.693, suggesting its less volatile than the S&P 500 by 30.722%.

Heron Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Heron Therapeutics pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

Heron Therapeutics quarterly revenues are $38.9M, which are larger than Plus Therapeutics quarterly revenues of --. Heron Therapeutics's net income of $2.6M is higher than Plus Therapeutics's net income of -$17.4M. Notably, Heron Therapeutics's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Heron Therapeutics is 2.06x versus 0.63x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Viatris has a net margin of 6.77% compared to Heron Therapeutics's net margin of -93.48%. Heron Therapeutics's return on equity of -- beat Viatris's return on equity of -20.24%.

Heron Therapeutics has a consensus price target of $6.25, signalling upside risk potential of 212.5%. On the other hand Viatris has an analysts' consensus of $11.3875 which suggests that it could grow by 22.84%. Given that Heron Therapeutics has higher upside potential than Viatris, analysts believe Heron Therapeutics is more attractive than Viatris.

Heron Therapeutics has a beta of 1.182, which suggesting that the stock is 18.163% more volatile than S&P 500. In comparison Viatris has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.435%.

Heron Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris offers a yield of 5.18% to investors and pays a quarterly dividend of $0.12 per share. Heron Therapeutics pays -- of its earnings as a dividend. Viatris pays out -90.63% of its earnings as a dividend.

Heron Therapeutics quarterly revenues are $38.9M, which are smaller than Viatris quarterly revenues of $3.3B. Heron Therapeutics's net income of $2.6M is higher than Viatris's net income of -$3B. Notably, Heron Therapeutics's price-to-earnings ratio is -- while Viatris's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Heron Therapeutics is 2.06x versus 0.77x for Viatris. Usually stocks with elevated PS ratios are considered overvalued.